Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07279038 · ClinicalTrials.gov registry record
Pivotal U.S. Clinical Validation of AI-COA® for Depression and Anxiety
A clinical trial, sponsored by Deliberate Solutions.
- Not yet
- Registry status
- 650
- Enrollment target
NCT07279038: Clinical Trial study, sponsored by Deliberate Solutions.
NCT07279038 is a clinical trial that has not yet begun recruiting, run by Deliberate Solutions. The registered enrollment target is 650 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07279038 has not yet begun recruiting, sponsored by Deliberate Solutions.
- NOT YET RECRUITING
- Registry status
- 650 participants
- Enrollment target
Study Summary
This study is a large-scale pivotal clinical validation of the AI-COA® software device. The purpose is to confirm the tool's accuracy and performance across a demographically diverse population of adults with Major Depressive Disorder (MDD), ensuring it functions fairly and reliably across different subgroups.
Primary Outcome
Concordance of HAM-D score between model and human raters
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 650 participants |
| Start Date | 2027-03-01 |
| Est. Completion | 2029-08-28 |
What is known before NCT07279038 opens enrollment
NCT07279038 is an observational study that tracks outcomes without assigning an intervention. The registered 650 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07279038 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07279038 about?
NCT07279038 is a clinical study titled "Pivotal U.S. Clinical Validation of AI-COA® for Depression and Anxiety". This study is a large-scale pivotal clinical validation of the AI-COA® software device. The purpose is to confirm the tool's accuracy and performance across a demographically diverse population of adults with Major Depressive Disorder (MDD), ensuring it functions fairly and reliably across different...
What is the current status of trial NCT07279038?
This trial is currently not yet recruiting. The enrollment target is 650 participants. The study started on 2027-03-01. Estimated completion is 2029-08-28.
Who is sponsoring clinical trial NCT07279038?
This trial is sponsored by Deliberate Solutions, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
- NCT05046600 · 650 participants
Registry of Arthrex Hand and Wrist Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI